Galmed Pharmaceuticals (NASDAQ: GLMD) CAO reports shares, options and RSUs

Rhea-AI Filing Summary

Galmed Pharmaceuticals Chief Accounting Officer Yohai Stenzler filed an initial ownership report showing direct holdings of 22,116 Ordinary Shares of GLMD. He also holds several equity awards and options that may convert into additional shares over time.

The filing lists options to purchase Ordinary Shares with an exercise price of 68.4000 per share, covering 222, 222, 111 and 222 underlying shares expiring between 2027 and 2030. Restricted share units include 2,083 units vesting on August 7, 2026, 23,333 units vesting in four installments from May 12, 2026 through November 12, 2027, and 25,000 units vesting between August 26, 2026 and August 26, 2028, all subject to his continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stenzler Yohai

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	22,116	D
Restricted Share Units	2,083(1)	D
Restricted Share Units	23,333(2)	D
Restricted Share Units	25,000(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	11/10/2020	11/10/2030	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	12/17/2019	12/17/2029	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	11/07/2017	11/07/2027	Ordinary Shares	111	$68.4	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	222	$68.4	D

Explanation of Responses:

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ Yohai Stenzler	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Galmed (GLMD) Form 3 filing by Yohai Stenzler show?

The Form 3 shows Chief Accounting Officer Yohai Stenzler’s initial ownership in Galmed. He directly holds 22,116 Ordinary Shares, plus several option grants and restricted share units that may convert into additional shares if vested and, for options, exercised.

How many Galmed (GLMD) Ordinary Shares does the CAO directly own?

Yohai Stenzler directly owns 22,116 Ordinary Shares of Galmed Pharmaceuticals. This figure reflects his current share position, separate from any options or restricted share units that could increase his effective economic exposure if they vest or are exercised.

What stock options does the Galmed (GLMD) CAO hold according to the Form 3?

The CAO holds options to purchase Ordinary Shares at an exercise price of 68.4000, covering 222, 222, 111, and 222 underlying shares. These options expire between November 7, 2027 and November 10, 2030, providing long-dated equity incentives.

What restricted share units (RSUs) are disclosed for Galmed (GLMD) CAO Yohai Stenzler?

He holds RSUs totaling 2,083, 23,333, and 25,000 units. These vest on schedules running from August 7, 2026 through August 26, 2028, with vesting conditioned on his continued service at Galmed Pharmaceuticals.

Are the equity awards in the Galmed (GLMD) Form 3 immediately vested?

No, the restricted share units vest over time. Schedules include single and installment vesting dates between May 12, 2026 and August 26, 2028, all subject to Yohai Stenzler’s continued service, aligning incentives with longer-term company performance.

Does the Galmed (GLMD) Form 3 indicate any recent insider buying or selling?

The Form 3 primarily reports existing holdings, not new trades. Transactions are coded as holdings with unknown transaction direction, indicating disclosure of current ownership rather than recent open-market purchases or sales by the Chief Accounting Officer.